Vedolizumab for chronic antibiotic-refractory pouchitis

Area of Science:

• Gastroenterology
• Immunology
• Surgical Gastroenterology

Background:

• Chronic antibiotic-refractory pouchitis (CARP) is a challenging complication following ileal pouch-anal anastomosis (IPAA).
• Limited data exist on the efficacy of vedolizumab, a gut-selective anti-integrin antibody, for CARP treatment.

Purpose of the Study:

• To assess the efficacy and safety of vedolizumab as induction therapy for patients with CARP.

Main Methods:

• A single-center, historic cohort study analyzed 19 CARP patients treated with vedolizumab from January 2015 to June 2017.
• Inclusion criteria included active pouchitis (modified pouch disease activity index [mPDAI] score ≥5) or clinician diagnosis.
• mPDAI scores were calculated using pouchoscopy and clinical visits pre-treatment and at 3-month post-therapy.

Main Results:

• 19 patients (mean age 26.7 years, 53% male) were included.
• 74% of patients showed improvement in endoscopic and total mPDAI scores (median change -2 units, P=0.031).
• Adverse events occurred in 11% of patients, and 21% required surgery for CARP.

Conclusions:

• Vedolizumab appears to be an effective and safe treatment option for CARP.
• Larger studies are needed to confirm these findings and establish vedolizumab's role in CARP management.